Compare LFMD & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | CGEN |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 191.1M |
| IPO Year | 2012 | 2001 |
| Metric | LFMD | CGEN |
|---|---|---|
| Price | $3.14 | $2.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $9.14 | $5.00 |
| AVG Volume (30 Days) | ★ 1.0M | 284.0K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 141.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,468,578.00 | N/A |
| Revenue This Year | $17.52 | N/A |
| Revenue Next Year | $18.73 | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.79 | N/A |
| 52 Week Low | $2.60 | $1.30 |
| 52 Week High | $7.32 | $3.24 |
| Indicator | LFMD | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 60.66 |
| Support Level | $3.00 | $2.54 |
| Resistance Level | $3.41 | $3.05 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 14.20 | 64.39 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.